Literature DB >> 19925944

Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals.

Charles E Rupprecht1, Deborah Briggs, Catherine M Brown, Richard Franka, Samuel L Katz, Harry D Kerr, Susan Lett, Robin Levis, Martin I Meltzer, William Schaffner, Paul R Cieslak.   

Abstract

After exposure, human rabies is preventable by prompt application of post-exposure prophylaxis. Historically, the total number of rabies vaccine doses administered during human prophylaxis has decreased, as modern biologics have improved and scientific knowledge has grown. A review of the literature on rabies virus pathogenesis, experimental animal studies, clinical trials, epidemiological surveillance, and economic analyses was conducted to determine the potential utility of reducing the current 5-dose intramuscular series of human rabies vaccine administered in the United States. Based upon the available evidence, a reduced schedule of cell-culture rabies vaccine, administered on days 0, 3, 7, and 14, given in conjunction with rabies immune globulin, was supported and recommended by the United States Advisory Committee on Immunization Practices.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925944     DOI: 10.1016/j.vaccine.2009.09.029

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.

Authors:  Jingchen Ma; Hongchang Wang; Jun Li; Likuan Chang; Yun Xie; Zhonglin Liu; Yuliang Zhao; Claudius Malerczyk; Malerczyk Claudius
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.

Authors:  RongCheng Li; YanPing Li; ShuQing Wen; HuiChun Wen; Yi Nong; Zhaojun Mo; Fang Xie; Michele Pellegrini
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen).

Authors:  B J Mahendra; Dh Ashwath Narayana; Sharad Agarkhedkar; H S Ravish; B R Harish; Shalaka Agarkhedkar; S N Madhusudana; Ashwin Belludi; Khaleel Ahmed; Rekha Jonnalagedda; Hoshang Vakil; Chiranjiwi Bhusal; Ashwani Kumar Arora
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Making rabies prophylaxis more economical: immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers.

Authors:  Guihua Huang; Huazhang Liu; Qing Tang; Pengcheng Yu; Xinxin Shen; Yibin Zhang; Xiangyi Liu; Qing Cao; Chuanxi Fu; Beiyan Liu; Ming Wang
Journal:  Hum Vaccin Immunother       Date:  2013-09-05       Impact factor: 3.452

5.  Clearance of attenuated rabies virus from brain tissues is required for long-term protection against CNS challenge with a pathogenic variant.

Authors:  Samantha A Garcia; Aurore Lebrun; Rhonda B Kean; D Craig Hooper
Journal:  J Neurovirol       Date:  2018-07-09       Impact factor: 2.643

6.  A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.

Authors:  Kerstin Westritschnig; Romana Hochreiter; Gerhard Wallner; Christa Firbas; Michael Schwameis; Bernd Jilma
Journal:  Hum Vaccin Immunother       Date:  2013-09-24       Impact factor: 3.452

7.  Analysis on the risks of severe adverse events in rabies post-exposure prophylaxis and appropriate decision-making procedure.

Authors:  Shichun Huang; Zhenggang Zhu; Li Cai; Zerong Zhu; Man Zhang; Quan Hu; Yuan Fang
Journal:  Hum Vaccin Immunother       Date:  2018-10-26       Impact factor: 3.452

8.  Integrin β1 Promotes Peripheral Entry by Rabies Virus.

Authors:  Lei Shuai; Jinliang Wang; Dandan Zhao; Zhiyuan Wen; Jinying Ge; Xijun He; Xijun Wang; Zhigao Bu
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

9.  Safety and immunogenicity of rabies vaccine as 4 - dose Essen Intramuscular regimen for post exposure prophylaxis: A non - randomized, comparative controlled study.

Authors:  Ravish S Haradanahalli; Rupsa Banerjee; Mysore Sudarshan Kalappa; Ashwath Narayana; Rachana R Annadani; Gangaboraiah Bilagumba
Journal:  Hum Vaccin Immunother       Date:  2021-02-23       Impact factor: 3.452

10.  A shorter post-exposure prophylaxis regimen for rabies, Pakistan.

Authors:  Naseem Salahuddin; Nadia Ansari; Muhammad Aftab Gohar
Journal:  Bull World Health Organ       Date:  2021-04-29       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.